Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study - Concepedia

Concepedia

Publication | Closed Access

Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

410

Citations

23

References

2012

Year

Hagop M. Kantarjian, Deborah A. Thomas, Jeffrey L. Jorgensen, Elias Jabbour, Partow Kebriaei, Michael Rytting, Sergernne York, Farhad Ravandi, Monica Kwari, Stefan Faderl,

The Lancet Oncology

Inotuzumab OzogamicinLymphoid NeoplasiaHematological MalignancyMedicineAnti-cd22–calecheamicin ConjugateImmunologyTumor ImmunityPharmacologyImmune Checkpoint InhibitorPharmacotherapyAnti-cancer AgentPhase 2ImmunotherapyOncologyCancer Research

References

	Year	Citations

Page 1

Page 1